Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2

Edge AI Solutions
AI Inference Device
DeviceEdge Jetson Series
DeviceEdge AI on ARM Series
AI Inference / Training System
MegaEdge PCIe Series
MegaEdge M.2 Series
MegaEdge MXM Series
AI Inference / Training Server
AI Accelerator & GPU
CoreEdge PCIe Card
I